ImmuCell reports Q3 2024 preliminary sales of $6.0M, up 11% YoY; backlog $7.3M

IMMUCELL CORP /DE/

2024-Q3 EPS reported -$0.34 revenue$18,742,040

Q3 2024 total sales $6.0M (+11% YoY); nine-month sales $18.7M (+51% YoY).
Twelve-month sales $23.8M (+46% YoY); production at 77% of ~$30M annual capacity.
Backlog of orders $7.3M; reflects strong demand as distributors replenish stocks.
Plans to submit Re-Tain NADA later this year after contract manufacturer resolves FDA issues.
Conference call on Nov 14, 2024 at 9:00 AM ET to discuss full Q3 results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.